Lin Chenying, An Haohua, Lin Jingna, Cao Yuejuan, Yang Zhen
Tianjin Union Medical Center, Tianjin Medical University, Tianjin, China.
Department of Endocrinology, Health Management Center, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China.
Front Endocrinol (Lausanne). 2025 Feb 19;16:1466428. doi: 10.3389/fendo.2025.1466428. eCollection 2025.
This study evaluated the incidence trends of early-onset (diagnosed at ages 15-39) and late-onset (diagnosed at age 40 and above) type 2 diabetes mellitus (T2DM) in the Asia-Pacific region, including the World Health Organization (WHO) South-East Asia Region (SEARO) and Western Pacific Region (WPRO), and assessed the impact of the COVID-19 pandemic.
Using data from the Global Burden of Diseases Study (GBD) 2021, we analyzed trends in age-standardized incidence rate (ASIR) using Join point regression to determine annual percentage change (APC). To assess the pandemic's impact, we calculated excess incidence for 2020 and 2021 by subtracting predicted ASIR from observed ASIR.
In recent years, particularly during the COVID-19 pandemic, the ASIR for early-onset T2DM in the Asia-Pacific region accelerated significantly. SEARO's APC rose from 2.24% between 2011-2019 to 5.45% between 2019-2021. Similarly, WPRO's APC increased from 1.71% between 1999-2017 to 5.01% between 2017-2021. In 2021, the ASIR for early-onset T2DM was 269.6 per 100,000 in WPRO and 248.4 per 100,000 in SEARO. Conversely, late-onset T2DM ASIR growth in SEARO slowed after 2017 (APC 1.92% for 2005-2017 . 1.04% for 2017-2021), while WPRO saw a decline (APC 1.06% for 2007-2017 . -1.10% for 2017-2021). During the COVID-19 pandemic in 2020 and 2021, the observed ASIR of early-onset T2DM in the Asia-Pacific region exceeded historical predictions, showing a positive excess in ASIR.
This study reveals a significant recent increase in early-onset T2DM incidence in the Asia-Pacific region, highlighting the need for targeted public health interventions.
本研究评估了亚太地区早发型(15 - 39岁确诊)和晚发型(40岁及以上确诊)2型糖尿病(T2DM)的发病趋势,包括世界卫生组织(WHO)东南亚区域(SEARO)和西太平洋区域(WPRO),并评估了新冠疫情的影响。
利用全球疾病负担研究(GBD)2021的数据,我们使用Join点回归分析年龄标准化发病率(ASIR)趋势,以确定年度百分比变化(APC)。为评估疫情的影响,我们通过从观察到的ASIR中减去预测的ASIR来计算2020年和2021年的超额发病率。
近年来,特别是在新冠疫情期间,亚太地区早发型T2DM的ASIR显著加速上升。SEARO的APC从2011 - 2019年的2.24%升至2019 - 2021年的5.45%。同样,WPRO的APC从1999 - 2017年的1.71%增至2017 - 2021年的5.01%。2021年,WPRO早发型T2DM的ASIR为每10万人269.6例,SEARO为每10万人248.4例。相反,SEARO晚发型T2DM的ASIR在2017年后增长放缓(2005 - 2017年APC为1.92%,2017 - 2021年为1.04%),而WPRO则出现下降(2007 - 2017年APC为1.06%,2017 - 2021年为 - 1.10%)。在2020年和2021年的新冠疫情期间,亚太地区观察到的早发型T2DM的ASIR超过了历史预测,ASIR呈现正超额。
本研究揭示了近期亚太地区早发型T2DM发病率显著上升,凸显了有针对性的公共卫生干预措施的必要性。